Is marijuana Schedule III now? Yes, but only for the limited group covered by the April 28, 2026 final rule: FDA-approved drug products containing marijuana and marijuana-related products within the rule’s stated state medical marijuana licensing scope. The broader proposal to move marijuana itself to Schedule III is a separate DEA proceeding, so it is not accurate to say that every marijuana product is now Schedule III.
Disclosure: TakeHempGummies.com may earn from qualifying links on other pages. This page has no product recommendation or purchase link.
What does “marijuana Schedule III” mean here?
Schedule III is a category in the federal Controlled Substances Act. The current Schedule III regulation has been in effect since April 28, 2026. For this question, the important part is not the category name by itself; it is which marijuana-related products the April rule actually placed there.
The April 28 rule says FDA-approved drug products containing marijuana are placed in Schedule III. It also describes a limited reach to marijuana, marijuana extracts, delta-9-THC, and other marijuana-plant compounds outside the federal hemp definition when they are included in an FDA-approved drug product or are subject to a state-issued medical marijuana license for making, distributing, or dispensing marijuana products for medical purposes.
What is the scope of the April 2026 final rule?
The Department of Justice and DEA published the final rule on April 28, 2026. Its title is Rescheduling of FDA-Approved Products, which is a useful clue to its limited focus.
| Record | What it covers | Date |
|---|---|---|
| Final rule | FDA-approved marijuana-containing drug products and the stated state medical marijuana license scope; it also changes related import, export, and registration rules. | April 28, 2026 |
| Current regulation | Schedule III regulations and permit provisions now in force. | In effect since April 28, 2026 |
| Broader proposal | A separate proceeding proposing to reschedule marijuana more broadly. | Notice published April 28, 2026 |
The related import and export permit rule specifically includes marijuana in a product subject to a state medical marijuana license. That is why a reader should not reduce the final rule to a simple headline about all marijuana becoming Schedule III.
How is the broader marijuana rescheduling proceeding different?
The broader proceeding is a proposed rule, not the same record as the final rule above. DEA’s April 28, 2026 marijuana rescheduling proposal says DEA would hold a hearing on a proposal to place marijuana in Schedule III; it also says the proposal was initially published on May 21, 2024.
That difference matters if you are asking, “When will marijuana become Schedule III?” The official record provided here tells you that a broader proposal and hearing process existed as of October 8, 2026. It does not give a final date for a broader change or resolve how any court order or later legal action may affect it.
Does this make all marijuana federally legal?
No. The April final rule is limited by its own terms, and the broader proceeding remains a separate record. State permission, an FDA-approved product, a proposed federal rule, and a court order are different legal records with different effects.
Federal hemp rules are separate, too. The 2018 Farm Bill removed hemp meeting the statutory delta-9-THC limit from the Controlled Substances Act, while preserving FDA authority over cannabis-derived products, according to the FDA’s cannabis regulation overview. For the consumer-product side of that distinction, see Federal Hemp Law in 2026.
What about medical marijuana and FDA-approved medicines?
“Medical marijuana” is not a shortcut that answers every federal question. The April rule expressly refers to FDA-approved drug products and its defined state medical marijuana licensing scope. FDA separately says it has approved certain cannabinoid medicines, while it has not approved the cannabis plant itself for medical use; NCCIH’s cannabis overview explains that distinction.
If your question is about a hemp gummy, a product label, or a lab report, do not assume this rescheduling record answers it. Start with the product’s cannabinoid details and the applicable rules explained in Who Regulates Hemp Gummies?.
What should you check next?
- Read the dated final rule and the separate proposed-rule notice, not only a headline.
- Check whether the product or activity fits the final rule’s FDA-approved-product or state medical-license language.
- Check the current eCFR text for the regulation in force.
- For a purchase, read the label and any batch report; Hemp Lab Report Units explains the terms you may see.
- For a real legal decision, have a qualified attorney review the current rule, jurisdiction, and any later court action.
As of October 8, 2026, the clean answer is: a limited April final rule is in force, while the broader marijuana Schedule III proposal is a separate proceeding. This is legal information, not legal advice.
By TakeHempGummies.com Consumer Research Desk